Mana.bio develops artificial intelligence–based platforms for drug delivery using lipid nanoparticles (LNPs). The company combines machine learning with nanotechnology to design, test, and refine LNP formulations through computational modeling and laboratory validation. Its technology focuses on extrahepatic tissue targeting and includes research on lung-targeted delivery and safety improvements through predictive modeling. Mana.bio has introduced ChatLNP, a tool that supports literature analysis, property prediction, and formulation optimization. The platform integrates experimental results with public data to enhance model accuracy and broaden its design capabilities for gene therapy and RNA-based medicines.